Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds노년층에서 COVID-19 감염 또는 BNT162b2 백신 후 체액성 면역 반응: 시간 경과에 따른 진화 및 보호 역치Article Published on 2022-06-012022-09-12 Journal: GeroScience [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age Anti-RBD IgG Antibody titer BNT162b2 vaccine COVID-19 COVID-19 infection decrease Dynamics Evolution first vaccination immune response Infection injection IQR Kinetics less maintain natural infection Older Patient patients with SARS-CoV-2 Protective SARS-CoV-2 serological test serology significantly higher Support symptom onset the median the SARS-CoV-2 the vaccine three groups threshold vaccination Vaccine vaccine group [DOI] 10.1007/s11357-022-00546-y PMC 바로가기 [Article Type] Article
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infectionCOVID-19 재감염 이력이 있는 개인에서 SARS-CoV-2 mRNA-1273 백신 2회 접종 후 항체 반응Case Reports Published on 2022-06-012022-09-12 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] antibody Antibody Response antispike protein IgG antibody booster Case report COVID-19 COVID-19 infections dose evaluated first vaccination Generalizability IgG immunologic response Infection initial Japanese mRNA-1273 vaccine Neutralizing Neutralizing activity neutralizing antibody patients with COVID-19 Protein Re-infection remained SARS-CoV-2 second vaccination vaccination Vaccinations Vaccine [DOI] 10.1016/j.ijid.2022.03.017 PMC 바로가기 [Article Type] Case Reports
Safety of an Inactivated SARS-CoV-2 Vaccine Among Healthcare Workers in Turkey: An Online Survey터키 의료 종사자의 비활성화된 SARS-CoV-2 백신의 안전성: 온라인 설문조사Article Published on 2022-05-242022-09-12 Journal: Balkan medical journal [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Administered age blood pressure CoronaVac coronavirus COVID-19 COVID-19 vaccine cross-sectional study determine disorder Dizziness dose Effect evaluate first vaccination Gender headache healthcare worker inactivated joint medication occurred Occurrence Pain participant Post-vaccine questionnaire redness risk factor Safety SARS-CoV-2 second dose second vaccination Sex side Side effect Side effects sociodemographic data Spread survey Thyroid vaccination Vaccine Vaccine hesitancy were recorded worker [DOI] 10.4274/balkanmedj.galenos.2022.2021-11-25 PMC 바로가기 [Article Type] Article
A Multicenter Cohort Study on the Adverse Effects Evaluation After Messenger RNA COVID-19 Vaccination Among Pregnant Healthcare Employees in Penang General Hospitals페낭 종합병원 임산부의 코로나19 메신저 RNA 예방접종 후 부작용 평가에 대한 다기관 코호트 연구Multicenter Study Published on 2022-05-232022-09-11 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 치료기술, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse effect adverse effects post vaccination age anomalies Anomaly APGAR score appear approval Birth weight conducted coronavirus COVID-19 COVID-19 vaccine drug Drug administration Effect employee first vaccination followed by food gestational age growth hospital Inference intrauterine growth restriction Malaysia messenger mother mRNA mRNA vaccine MVP Neonatal Neonatal outcomes Neonate participant Penang Pregnancy pregnancy outcome pregnant pregnant women public health Regulatory reported retrospective cohort study RNA Safe safety of mRNA vaccine. safety profile SARS-CoV-2 second trimester Seven Spread subject the disease the mean trimester US Food and Drug Administration Vaccine Vaccine development widespread [DOI] 10.3389/fpubh.2022.876966 PMC 바로가기 [Article Type] Multicenter Study
Trajectory of long covid symptoms after covid-19 vaccination: community based cohort studyObservational Study Published on 2022-05-182022-10-04 Journal: The BMJ [Category] COVID19(2023년), SARS, 임상, [키워드] 95% confidence interval Adenovirus age association cohort study Community contribute COVID-19 Infection Survey decrease dose Evidence first vaccination Follow-up follow-up period Health Health status Hospital admission increase Infection initial likelihood mRNA office outcome participant Participants positive Presence reduction in reported SARS-COV-2 infection second dose second vaccination severity Sociodemographic characteristics Statistics subsequent suggested sustained Symptom the median trajectory vaccination Vaccine vaccine dose women [DOI] 10.1136/bmj-2021-069676 PMC 바로가기 [Article Type] Observational Study
Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine혈청전환 패널은 mRNA-1273 백신 투여 후 항-SARS-CoV-2 항체 개발을 보여줍니다Article Published on 2022-05-112022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] administration analyzed anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibody Antibody Response anticipated collected COVID-19 disease facilitate first vaccination healthcare worker IgG Immunity immunoglobulins Immunological response individual injection Moderna mRNA-1273 vaccine older subjects overcome pandemic Panel positive positive response pre-vaccination SARS-CoV-2 second dose Seroconversion Seroconversion panel Serological assay significantly subject tested the vaccine vaccination Vaccine viral disease [DOI] 10.1016/j.vaccine.2022.04.006 PMC 바로가기 [Article Type] Article
Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?기존의 항바이러스 백신에 대한 항체 반응이 최적이 아닌 개인이 SARS-CoV-2 mRNA 백신 접종을 통해 적절한 항체를 얻을 수 있습니까?Article Published on 2022-05-032022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adequate Anti-spike anti-spike antibodies anti-spike antibody antibody Antibody titers BNT162b2 BNT162b2 mRNA vaccine Can Chickenpox Conventional conventional vaccines coronavirus coronavirus disease Coronavirus disease 2019 detectable dose exhibited first vaccination HCW HCWs healthcare worker Healthcare workers hepatitis B immune response immune responses individual Japan measles mRNA mRNA vaccine mumps Neutralizing neutralizing antibody nosocomial Nosocomial infection of BNT162b2 Prevent prospective cohort study reduced respiratory Responder responders response rubella SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody second vaccination severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 vaccination Vaccine was measured were measured [DOI] 10.3390/v14050956 PMC 바로가기 [Article Type] Article
Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab리툭시맙으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 백신 접종에 대한 혈청학적 반응과 관련된 요인Article Published on 2022-05-022022-09-12 Journal: JAMA Network Open [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] accumulated age analyzed angiotensin-converting enzyme 2 Anti-RBD IgG anti-receptor-binding domain Anti-spike anti-Spike IgG antibodies antibody B cells B-cell binding antibody CD19+ CD4+ T-cell CD8+ T-cell cellular response cohort study conducted COVID-19 infection Cutoff cutoff value Diagnosis disease dose Factor first vaccination Follow-up greater identify IgG IgG antibodies Immunoglobulin interferon gamma median monoclonal antibody Multiple multiple sclerosis Neutralizing outcome outcomes Patient patients evaluated peptide pool positive response positive test result proportion prospective cohort study quantitation RBD reached response rituximab SARS-CoV-2 sclerosis serological response spot-forming unit T-cell Response the median Treatment university hospital vaccination vaccine response Vaccines were assessed were measured women [DOI] 10.1001/jamanetworkopen.2022.11497 PMC 바로가기 [Article Type] Article
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)면역매개염증질환(RESCUE)에서 DMARD 치료를 일시적으로 중단한 후 COVID-19 ChAdOx1nCov-19 및 BNT162b 백신에 대한 항체 반응Randomized Controlled Trial Published on 2022-05-012022-09-11 Journal: RMD Open [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제, [키워드] Adult patients Antibody Response Antibody responses antirheumatic agents AstraZeneca AZ vaccine baseline biologic BNT162b Control control group control groups controls COVID-19 csDMARD dose Final first and second dose first dose first vaccination group groups IgG Immune-mediated immunogenicity inflammatory disease Messenger RNA multicentre not significantly different Patient Pfizer Protein randomised randomised controlled trial registration number response S1/S2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV2 second dose second vaccination Seroconversion seroconversion rate seroconversion rates significantly lower the antibody response the mean therapy titre titres U/mL vaccination Vaccine were measured [DOI] 10.1136/rmdopen-2022-002301 PMC 바로가기 [Article Type] Randomized Controlled Trial
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialHIV-1 감염 여부에 관계없이 살고 있는 사람들을 대상으로 한 SARS-CoV-2 재조합 스파이크 단백질 나노입자 백신의 면역원성과 안전성: 무작위, 대조, 2A/2B상 시험Clinical Trial Published on 2022-05-012022-09-12 Journal: The Lancet. HIV [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 1:1 amplification angiotensin-converting enzyme 2 anti-Spike IgG antibody Antiretroviral therapy article assigned baseline clinical Coalition Cohort COVID-19 COVID-19 vaccine death dosage Efficacy and safety ELISA endpoints enrolled enrolment evaluated first vaccination geometric mean titre GMT GMTs HIV-1 HIV-1 viral HIV-negative humoral immune response immunogenicity increased risk individual injection interim analysis intervention group Intramuscular injection less Local Matrix-M Melinda Gate multicentre neutralising antibody titres Novavax NVX-CoV2373 NVX-CoV2373 vaccine observer-blinded occurred PACTR202009726132275 participant Participants paucity of data Placebo placebo-controlled provided randomised Randomly reactive receive Recombinant spike protein Registered registry remained reported safety analysis SARS-CoV-2 SARS-CoV-2 nucleic acid SCR SCRs second vaccination Serious Adverse Event Serious Adverse Events seroconversion rate serostatus South Africa stratified study group Support systemic adverse event the placebo group the vaccine Trial vaccination Vaccine vaccine immunogenicity Volume was used were assessed [DOI] 10.1016/S2352-3018(22)00041-8 PMC 바로가기 [Article Type] Clinical Trial